Cellular Cancer Markers (Contemporary Biomedicine Book 12)

In Cellular Cancer Markers leading pathologists and physicians review today's most promising cellular cancer markers, an important emerging class of prognostic markers that can be used in the clinical evaluation of cancer patients. The markers reviewed have been chosen because they are biologically relevant to the growth of cells and possess an accurate and reproducible assay for detection. They also are predictors of tumor behavior, are useful in making clinical decisions, and are cost effective. Cellular Cancer Markers provides a status report for markers of tumor cell activation, proliferation, and longevity that makes possible an informed judgment regarding the value of many newly proposed tumor markers. It also offers insight into the latest approaches to diagnosing cancer and an appreciation of how these marker-based tests can clarify the prognosis of cancer.

In Cellular Cancer Markers leading pathologists and physicians review today's most promising cellular cancer markers, an important emerging class of prognostic markers that can be used in the clinical evaluation of cancer patients. The markers reviewed have been chosen because they are biologically relevant to the growth of cells and possess an accurate and reproducible assay for detection. They also are predictors of tumor behavior, are useful in making clinical decisions, and are cost effective.

Cellular Cancer Markers provides a status report for markers of tumor cell activation, proliferation, and longevity that makes possible an informed judgment regarding the value of many newly proposed tumor markers. It also offers insight into the latest approaches to diagnosing cancer and an appreciation of how these marker-based tests can clarify the prognosis of cancer.

Booknews

The term tumor markers has traditionally referred to those soluble antigens, hormones, or enzymes that appear in body fluids as a result of an associated clinical cancer. The present volume considers a new class of compounds consisting of cell-associated proteins and nucleic acids, both of which characteristically are not released into serum or other body fluids in any appreciable quantity. Contributions discuss the role(s) of these markers in the mechanism of malignant transformation as well as their effects on clinical outcome, new modes of therapy that molecular approaches are identifying, and issues concerning cost-effective application of the growing number of new tumor markers. Annotation c. Book News, Inc., Portland, OR (booknews.com)

Front Matter....Pages i-xi Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer....Pages 1-16 ras Proto-Oncogene Activation in Human Malignancy....Pages 17-52 C- myc as a Tumor Marker for Primary Human Cancers....Pages 53-76 p53 in Human Cancer....Pages 77-110 Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies....Pages 111-138 Genetic Alterations in Colon Cancer....Pages 139-189 Genetic Changes in Breast Cancer....Pages 191-208 Genetic Alterations in Lung Cancer....Pages 209-229 Wilms Tumor-Susceptibility Loci....Pages 231-255 Non-Hodgkin’s Lymphomas....Pages 257-288 Phenotypic Expression of Hodgkin’s Disease....Pages 289-334 Melanoma Markers....Pages 335-350 Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma....Pages 351-374 P-Glycoproteins in Tumors....Pages 375-391 Genetically Engineered Antitumor Monoclonal Antibodies....Pages 393-432 Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of cAMP-Dependent Protein Kinase....Pages 433-454 Summary and Perspective....Pages 455-477 Back Matter....Pages 479-484